Literature DB >> 11529856

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).

D Intini1, L Baldini, S Fabris, L Lombardi, G Ciceri, A T Maiolo, A Neri.   

Abstract

The t(4;14)(p16.3;q32) in multiple myeloma (MM) leads to an apparent deregulation of the FGFR3 and WHSC1/MMSET genes. FGFR3 mutations, known to be associated with genetic skeletal disorders, have also been identified in a few cases of MM (mainly cell lines) with t(4;14). We investigated FGFR3 mutations in a series of 53 MM cases; 11 cases with t(4;14) and FGFR3 overexpression were analysed using reverse transcription polymerase chain reaction, while the remaining cases were studied at DNA level. The Arg248Cys mutation, which is associated with some lethal forms of skeletal disorders, was found in one case with t(4;14). Our results indicate that FGFR3 mutations occur in only a small fraction of MM cases with t(4;14).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529856     DOI: 10.1046/j.1365-2141.2001.02957.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.

Authors:  Pavel Krejci; Shunichi Murakami; Jirina Prochazkova; Lukas Trantirek; Katarina Chlebova; Zhufeng Ouyang; Anie Aklian; Jiri Smutny; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

2.  Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.

Authors:  Wei-Hua Qiu; Bing-Sen Zhou; Peiguo-G Chu; Wen-Gang Chen; Christopher Chung; Jennifer Shih; Paul Hwu; Christopher Yeh; Richard Lopez; Yun Yen
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

Review 3.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

4.  A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Authors:  Min Jin; Ying Yu; Huabing Qi; Yangli Xie; Nan Su; Xiaofeng Wang; Qiaoyan Tan; Fengtao Luo; Ying Zhu; Quan Wang; Xiaolan Du; Cory J Xian; Peng Liu; Haiyang Huang; Yue Shen; Chu-Xia Deng; Di Chen; Lin Chen
Journal:  Hum Mol Genet       Date:  2012-09-26       Impact factor: 6.150

5.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

6.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

Review 7.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

8.  Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Authors:  F R Lamont; D C Tomlinson; P A Cooper; S D Shnyder; J D Chester; M A Knowles
Journal:  Br J Cancer       Date:  2010-11-30       Impact factor: 7.640

9.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Authors:  D C Tomlinson; C D Hurst; M A Knowles
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

10.  The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies.

Authors:  A Kalff; A Spencer
Journal:  Blood Cancer J       Date:  2012-09-07       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.